Insight Surgery
AI-enabled digital planning and personalised surgical devices delivered in days, not weeks
| Deal Type | Equity |
|---|---|
| Sector | HealthTech & Digital Health |
| Geography | UK / United States |
| Stage / Vintage | Growth stage; 2026 equity round |
| Total Fundraise | GBP 5.0M |
| Minimum Ticket | N/D |
Opportunity Overview
Insight Surgery provides digital planning and patient-specific surgical guides for orthopaedic surgery through its EmbedMed platform. Patient imaging is converted into 3D surgical plans and bespoke devices that translate the plan into the operating theatre. The company highlights FDA clearance, ISO 13485 certification, broad regulatory clearances, US and UK manufacturing capabilities, and a delivery cycle of around 10 working days versus roughly six weeks for competitors. 2025 sales were approximately GBP 1M, with high gross margins per device and accelerating US traction after new hospital customers and reimbursement progress. The 2026 round is intended to scale US commercial infrastructure, expand manufacturing, add AI into the platform and support new high-volume device categories.
Key Highlights
- Patent-protected EmbedMed platform, with AI intended to automate design, manufacture and delivery workflows.
- Widest FDA clearances on the market and ISO 13485 certification, supporting differentiated regulatory positioning.
- Over 1,000 devices delivered and a growing US customer base including major hospitals and health systems.
- US monthly revenue increased materially during 2025, with further US pipeline referenced for Q1 2026.
- Current round is GBP 5.0M, which the company is aiming to close by the end of the year.
GCC Relevance
GCC relevance is thematic rather than currently contractual. The opportunity aligns with regional healthcare modernisation, precision surgery, orthopaedic capacity expansion and medical manufacturing ambitions, but the materials do not disclose existing Middle East customers or a defined Gulf rollout plan.